Streptococcus agalactiae

A vaccine to Streptococcus agalactiae has been identified as an international priority to reduce the burden of disease and decrease antibiotic use (WHO, 2015). RVX-002 is being developed to address this unmet clinical need.


Group B Streptococcus (GBS), also referred to as Streptococcus agalactiae, is an opportunistic pathogen that colonises the gastrointestinal and genitourinary tracts of up to 50% of healthy adults globally. GBS is estimated to cause 300,000+ cases of invasive neonatal disease (e.g. pneumonia, septicaemia and meningitis) globally, resulting in 90,000 deaths. GBS is also responsible for significant morbidity in pregnant women and is a growing problem in the elderly and immunocompromised adults.

We have established preclinical models closely mimicking GBS vaginal colonisation, invasive disease and mother-to-neonate vertical transmission. These models are a key pillar in the preclinical validation of our novel vaccine candidates.

Our Research

Studies evaluating the protective efficacy of investigational polysaccharide-based GBS vaccine in pregnant women have been conducted in Europe and Africa; but none of them has yet reached the market. Our goal is to develop a protein-based cross-serotype GBS vaccine for maternal immunisation to prevent early-life invasive disease and reduce perinatal antibiotic use.

Get in touch

To learn more about our RVX-002 Streptococcus Pyogenes vaccine please click on the below button